Healthcare doesn’t care about tariffs. JNJ is proving it.
Whereas the S&P 500 is flat on the yr, Johnson and Johnson is up over 17%.
That sort of separation doesn’t come from momentum merchants chasing a reputation. It comes from institutional cash making a deliberate resolution about the place it desires to be.
The enterprise is what despatched them there.
This autumn 2025 income got here in at $24.56 billion, up 9.1% yr over yr and forward of estimates.
The oncology phase is driving the expansion. Darzalex and Carvykti are gaining share in a number of myeloma, one of the vital aggressively handled blood cancers on the planet.
The MedTech phase grew 7.5%, led by cardiovascular and surgical merchandise. The corporate pushed by way of 51 drug approvals and submissions in 2025 alone.
Administration guided 2026 adjusted earnings to $11.53 per share on $100.5 billion in income. They issued that steering in January, earlier than the tariff noise and the geopolitical mess.
JNJ’s income comes from prescription drugs and medical units. These don’t sit in delivery containers at a port ready to get repriced.
The chart is catching as much as the enterprise.
EMAs are stacked on each the every day and the weekly timeframe. An EMA, or exponential shifting common, is a line that tracks the typical worth of a inventory over a set interval, weighted towards current costs.
When the short-term EMA sits above the longer-term EMA and each are rising, it means patrons have been constantly in management throughout a number of timeframes, not only one.
The 8-day EMA is above the 20-day on the every day chart, each are trending greater, and worth is sitting properly above the 200-day shifting common at $195.
RSI is sitting at 52. RSI measures momentum on a scale from 0 to 100, the place values above 50 point out that patrons are in management.
At 52, this inventory will not be overbought. There’s room to run earlier than it will get prolonged.
The inventory has been consolidating in a good vary just under the highs close to $248. That degree has acted as a double high, which means worth has examined that resistance twice with out breaking by way of.
Sellers have proven up there twice. What occurs the third time is the commerce.
On the every day timeframe, the squeeze has not fired but. A squeeze is when worth compresses into an more and more slim vary, constructing vitality earlier than a directional transfer. The tighter the coil, the extra important the discharge tends to be.
Your Motion Plan
Earnings land on April 14. That’s subsequent week.
Q1 estimates are calling for $23.6 billion in income and $2.68 in adjusted EPS. JNJ has overwhelmed income estimates in every of the final 4 quarters.
The enterprise development and the chart development are pointing in the identical course heading into that report.
A robust quantity right here doesn’t simply validate the thesis. It removes the final motive for a vendor to lean on the double high.
Whether or not it breaks or fails is the setup. If the squeeze fires and worth clears $248 on quantity, that modifications the dialog.
If earnings are available sturdy and the inventory gaps greater, that double high turns into a flooring reasonably than a ceiling.
I don’t but have a place at JNJ.
When the setup provides me what I want, I’ll publish the commerce in Every day Earnings Stay.